255 related articles for article (PubMed ID: 32208517)
1. Metabolic factors contribute to T-cell inhibition in the ovarian cancer ascites.
Gong Y; Yang J; Wang Y; Xue L; Wang J
Int J Cancer; 2020 Oct; 147(7):1768-1777. PubMed ID: 32208517
[TBL] [Abstract][Full Text] [Related]
2. Computational modeling of malignant ascites reveals CCL5-SDC4 interaction in the immune microenvironment of ovarian cancer.
Kim S; Han Y; Kim SI; Lee J; Jo H; Wang W; Cho U; Park WY; Rando TA; Dhanasekaran DN; Song YS
Mol Carcinog; 2021 May; 60(5):297-312. PubMed ID: 33721368
[TBL] [Abstract][Full Text] [Related]
3. Emerging perspectives on growth factor metabolic relationships in the ovarian cancer ascites environment.
Monavarian M; Elhaw AT; Tang PW; Javed Z; Shonibare Z; Scalise CB; Arend R; Jolly MK; Sewell-Loftin MK; Hempel N; Mythreye K
Semin Cancer Biol; 2022 Nov; 86(Pt 2):709-719. PubMed ID: 35259492
[TBL] [Abstract][Full Text] [Related]
4. Electrolyte imbalance causes suppression of NK and T cell effector function in malignant ascites.
Hrvat A; Schmidt M; Wagner B; Zwanziger D; Kimmig R; Volbracht L; Brandau S; Mallmann-Gottschalk N
J Exp Clin Cancer Res; 2023 Sep; 42(1):235. PubMed ID: 37684704
[TBL] [Abstract][Full Text] [Related]
5. Ovarian cancer-associated ascites demonstrates altered immune environment: implications for antitumor immunity.
Giuntoli RL; Webb TJ; Zoso A; Rogers O; Diaz-Montes TP; Bristow RE; Oelke M
Anticancer Res; 2009 Aug; 29(8):2875-84. PubMed ID: 19661290
[TBL] [Abstract][Full Text] [Related]
6. IRE1α-XBP1 controls T cell function in ovarian cancer by regulating mitochondrial activity.
Song M; Sandoval TA; Chae CS; Chopra S; Tan C; Rutkowski MR; Raundhal M; Chaurio RA; Payne KK; Konrad C; Bettigole SE; Shin HR; Crowley MJP; Cerliani JP; Kossenkov AV; Motorykin I; Zhang S; Manfredi G; Zamarin D; Holcomb K; Rodriguez PC; Rabinovich GA; Conejo-Garcia JR; Glimcher LH; Cubillos-Ruiz JR
Nature; 2018 Oct; 562(7727):423-428. PubMed ID: 30305738
[TBL] [Abstract][Full Text] [Related]
7. Modification of the Tumor Microenvironment in KRAS or c-MYC-Induced Ovarian Cancer-Associated Peritonitis.
Yoshida M; Taguchi A; Kawana K; Adachi K; Kawata A; Ogishima J; Nakamura H; Fujimoto A; Sato M; Inoue T; Nishida H; Furuya H; Tomio K; Arimoto T; Koga K; Wada-Hiraike O; Oda K; Nagamatsu T; Kiyono T; Osuga Y; Fujii T
PLoS One; 2016; 11(8):e0160330. PubMed ID: 27483433
[TBL] [Abstract][Full Text] [Related]
8. Ascites modulates cancer cell behavior, contributing to tumor heterogeneity in ovarian cancer.
Kim S; Kim B; Song YS
Cancer Sci; 2016 Sep; 107(9):1173-8. PubMed ID: 27297561
[TBL] [Abstract][Full Text] [Related]
9. Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up.
Rudlowski C; Pickart AK; Fuhljahn C; Friepoertner T; Schlehe B; Biesterfeld S; Schroeder W
Int J Gynecol Cancer; 2006; 16 Suppl 1():183-9. PubMed ID: 16515588
[TBL] [Abstract][Full Text] [Related]
10. Influence of hypoxia inducible factors on the immune microenvironment in ovarian cancer.
Duechler M; Peczek L; Szubert M; Suzin J
Anticancer Res; 2014 Jun; 34(6):2811-9. PubMed ID: 24922644
[TBL] [Abstract][Full Text] [Related]
11. Ascites from ovarian cancer patients stimulates MUC16 mucin expression and secretion in human peritoneal mesothelial cells through an Akt-dependent pathway.
Matte I; Garde-Granger P; Bessette P; Piché A
BMC Cancer; 2019 Apr; 19(1):406. PubMed ID: 31039761
[TBL] [Abstract][Full Text] [Related]
12. CYR61, a potential biomarker of tumor inflammatory response in epithelial ovarian cancer microenvironment of tumor progress.
Shi J; Huo R; Li N; Li H; Zhai T; Li H; Shen B; Ye J; Fu R; Di W
BMC Cancer; 2019 Nov; 19(1):1140. PubMed ID: 31766991
[TBL] [Abstract][Full Text] [Related]
13. Metabolic markers and HSP60 in chemonaive serous solid ovarian cancer versus ascites.
Hjerpe E; Brage SE; Frostvik Stolt M; Johansson H; Shoshan M; Avall-Lundqvist E
Int J Gynecol Cancer; 2014 Oct; 24(8):1389-94. PubMed ID: 25188891
[TBL] [Abstract][Full Text] [Related]
14. The Epithelial-Mesenchymal Transition Initiated by Malignant Ascites Underlies the Transmesothelial Invasion of Ovarian Cancer Cells.
Pakuła M; Mikuła-Pietrasik J; Witucka A; Kostka-Jeziorny K; Uruski P; Moszyński R; Naumowicz E; Sajdak S; Tykarski A; Książek K
Int J Mol Sci; 2019 Jan; 20(1):. PubMed ID: 30609691
[TBL] [Abstract][Full Text] [Related]
15. Malignant ascites occurs most often in patients with high-grade serous papillary ovarian cancer at initial diagnosis: a retrospective analysis of 191 women treated at Bayreuth Hospital, 2006-2015.
Krugmann J; Schwarz CL; Melcher B; Sterlacci W; Ozalinskaite A; Lermann J; Agaimy A; Vieth M
Arch Gynecol Obstet; 2019 Feb; 299(2):515-523. PubMed ID: 30415435
[TBL] [Abstract][Full Text] [Related]
16. Different Lipid Regulation in Ovarian Cancer: Inhibition of the Immune System.
Wefers C; Duiveman-de Boer T; Zusterzeel PLM; Massuger LFAG; Fuchs D; Torensma R; Wheelock CE; de Vries IJM
Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29342108
[TBL] [Abstract][Full Text] [Related]
17. Acidic ascites inhibits ovarian cancer cell proliferation and correlates with the metabolomic, lipidomic and inflammatory phenotype of human patients.
Yang Q; Bae G; Nadiradze G; Castagna A; Berezhnoy G; Zizmare L; Kulkarni A; Singh Y; Weinreich FJ; Kommoss S; Reymond MA; Trautwein C
J Transl Med; 2022 Dec; 20(1):581. PubMed ID: 36503580
[TBL] [Abstract][Full Text] [Related]
18. Targeting myeloid cells in the tumor microenvironment enhances vaccine efficacy in murine epithelial ovarian cancer.
Khan AN; Kolomeyevskaya N; Singel KL; Grimm MJ; Moysich KB; Daudi S; Grzankowski KS; Lele S; Ylagan L; Webster GA; Abrams SI; Odunsi K; Segal BH
Oncotarget; 2015 May; 6(13):11310-26. PubMed ID: 25888637
[TBL] [Abstract][Full Text] [Related]
19. Biochemical composition of malignant ascites determines high aggressiveness of undifferentiated ovarian tumors.
Mikuła-Pietrasik J; Uruski P; Szubert S; Moszyński R; Szpurek D; Sajdak S; Tykarski A; Książek K
Med Oncol; 2016 Aug; 33(8):94. PubMed ID: 27431203
[TBL] [Abstract][Full Text] [Related]
20. Proinflammatory and immunosuppressive serum, ascites and cyst fluid cytokines in patients with early and advanced ovarian cancer and benign ovarian tumors.
Nowak M; Glowacka E; Szpakowski M; Szyllo K; Malinowski A; Kulig A; Tchorzewski H; Wilczynski J
Neuro Endocrinol Lett; 2010; 31(3):375-83. PubMed ID: 20588232
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
